Background-The prognostic impact of ECG left ventricular strain and left ventricular hypertrophy (LVH) in asymptomatic aortic stenosis is not well described. Methods and Results-Data were obtained in asymptomatic patients randomized to simvastatin/ezetimibe combination versus placebo in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Primary end point was the first of myocardial infarction, nonhemorrhagic stroke, heart failure, aortic valve replacement, or cardiovascular death. The predictive value of ECG left ventricular strain (defined as T-wave inversion in leads V 4 through V 6 ) and LVH, assessed by Sokolow-Lyon voltage criteria (R V5-6 ϩS V1 Ն35 mV) and Cornell voltage-duration criteria {[RaVLϩS V3 ϩ(6 mV in women)]ϫQRS duration Ն2440 mV ⅐ ms}, was evaluated by adjustment for other prognostic covariates. A total of 1533 patients were followed for 4.3Ϯ0.8 years (6592 patient-years of follow-up), and 627 cardiovascular events occurred. ECG strain was present in 340 patients (23.6%), with LVH by Sokolow-Lyon voltage in 260 (17.1%) and by Cornell voltage-duration product in 220 (14.6%). In multivariable analyses, ECG left ventricular strain was associated with 3.1-fold higher risk of in-study myocardial infarction (95% confidence interval, 1.4 -6.8; Pϭ0.004). Similarly, ECG LVH by both criteria predicted, compared with no ECG LVH, 5.8-fold higher risk of heart failure (95% confidence interval, 2.0 -16.8), 2.0-fold higher risk of aortic valve replacement (95% confidence interval, 1.3-3.1; both Pϭ0.001), and 2.5-fold higher risk of a combined end point of myocardial infarction, heart failure, or cardiovascular death (95% confidence interval, 1.3-4.9; Pϭ0.008). Conclusions-ECG left ventricular strain and LVH were independently predictive of poor prognosis in patients with asymptomatic aortic stenosis. Clinical Trial Registrationhttp://www.clinicaltrials.gov. Unique identifier: NCT00092677. (Circulation. 2012;125:346-353.)
T he classic ECG patterns of left ventricular (LV) strain and LV hypertrophy (LVH) are independent predictors of poor prognosis and death in patients with aortic stenosis (AS) on the waiting list for aortic valve replacement (AVR). 1 Moreover, ECG signs of LV strain and LVH have been shown to be associated with a shorter asymptomatic period before onset of symptoms requiring AVR. 2 Because symptom onset is an accepted adverse sign in severe AS 3 and the ECG is a low-cost and widely available examination that can be interpreted without expert knowledge, ECG criteria for LV strain and LVH are appealing in asymptomatic patients with mild to moderate AS. However, the independent relation of ECG LV strain and LVH to risk of cardiovascular morbidity and mortality during watchful waiting in patients with asymp-tomatic AS has not been well described. Thus, the present study examined the associations of ECG LV strain and LVH on resting ECG with the risk of cardiovascular morbidity and mortality during follow-up of asymptomatic patients with mild to moderate AS.
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Methods
Study Population
The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study was a multicenter, randomized, double-blind, placebo-controlled study investigating whether intensive lipid lowering with simvastatin/ ezetimibe combination versus placebo could reduce the need for AVR and risk of cardiovascular morbidity and mortality in 1873 patients, aged 45 to 85 years, with asymptomatic AS (defined as echocardiographic aortic valve thickening accompanied by a Doppler-measured aortic peak flow velocity Ն2.5 and Յ4.0 m/s and normal systolic LV function). The main outcomes including complete study protocol, study design, organization, clinical measures, exclusion criteria (most importantly, systolic heart failure, diabetes mellitus, and known ischemic heart disease) and baseline characteristics have been published previously. 4, 5 This study uses prespecified analysis of prospectively collected data from baseline and annual in-study visits in the SEAS and the SEAS ECG substudy to investigate whether ECG LV strain and LVH are independently predictive of poor prognosis in patients with asymptomatic AS.
Electrocardiography
ECG study protocol, reading procedures, and reproducibility have been published. 6 In short, ECGs were recorded at baseline and then annually at the local study centers, after which they were sent to the central ECG core laboratory at The Heart Center, Rigshospitalet, Denmark. A physician blinded to the randomization and clinical data read and transferred all ECGs directly to a database by use of the Minnesota codes, in accordance with recent suggestions. 7 ECG strain was defined as T-wave inversion in leads V 4 through V 6 because this reflects peak aortic jet velocity better than ST-segment depression, 6 and LVH was defined as Sokolow-Lyon voltage (RV 5-6 ϩSV 1 ) Ն35 mV and Cornell voltage-duration product {[RaVLϩS V3 ϩ(6 mV in women)]ϫQRS duration} Ն2440 mV ⅐ ms.
Echocardiography
Echocardiographic study protocol, reading procedures, and reproducibility have been published. 8 In short, transthoracic echocardiograms were read blinded to the randomization and study visits at the SEAS echocardiographic core laboratory, located at Haukeland University Hospital in Bergen, Norway. Aortic valve area was calculated with the use of the continuity equation, in accordance with recent recommendations. 9 Quantitative echocardiography was performed following the American Society of Echocardiography guidelines. 10
End Points
All end points in the main study were classified by an end point classification committee blinded to randomization according to a prespecified end point manual outlined by the SEAS Steering Committee. 5 Specific end points were as follows: (1) sudden cardiac death (defined as either witnessed instantaneous unexpected death occurring without any preceding symptoms, unwitnessed unexpected death, if other cause of death was excluded with reasonable certainty [ie, patients with known signs, symptoms, or other fatal disease when last observed], or cardiac death occurring Ͻ24 hours after onset of cardiac symptoms [eg, acute pulmonary edema or cardiogenic shock]); (2) cardiovascular death (defined as death from complications of myocardial infarction, progressive heart failure, cerebrovascular disease, complications of cardiac surgery or intervention, other cardiac or cardiovascular diseases including sudden cardiac death as defined above); (3) AVR (defined as AVR as a single operative procedure or performed in combination with coronary artery bypass graft); (4) heart failure (defined as date of hospitalization for congestive heart failure, excluding patients with AVR, known heart failure, aortic valve area Ͼ1.0 cm 2 , and/or known heart disease, aside from AS, which could have contributed to the development of congestive heart failure); (5) nonhemorrhagic stroke (defined as a focal neurological deficit, lasting Ն24 hours, or until death [if death occurs Ͻ24 hours after onset of neurological symptoms], in the absence of signs of bleeding on computerized tomography, magnetic resonance imaging, or spinal fluid analysis); and (6) nonfatal and fatal myocardial infarction (defined as typical rise and gradual fall of troponin or rapid rise and fall of creatine kinase-MB with the addition of at least 1 of the following: ischemic symptoms, ischemic ECG changes [development of pathological Q waves, ST-segment elevation, ST-segment depression, inversion of T waves in at least 2 leads], and/or percutaneous coronary intervention with significant coronary stenosis/thrombus). Finally, we assessed the risk of a combined end point (ie, the first of nonfatal myocardial infarction, heart failure, or cardiovascular death).
Statistical Analysis
Data were analyzed with the use of Statistical Analytical Software version 9.1 (SAS, Cary, NC). Continuous data are expressed as meanϮSD and categorical variables as proportions. All continuous variables except QRS duration, which was assessed in interaction with ECG LVH as a categorical variable of Ն120 ms versus Ͻ120 ms, were normal. Differences in continuous variables were evaluated by use of t tests (with unweighted mean analysis due to unequal sample size) and by 2 tests for categorical data. The impact of simvastatin/ezetimibe combination versus placebo on progression in ECG LV strain and LVH was assessed in a mixed model, with the use of serial values of annual in-treatment ECG reexaminations. The relations of ECG LV strain and LVH to all cause-mortality and other end points (ie, myocardial infarction, nonhemorrhagic stroke, heart failure, AVR, sudden cardiac death, and cardiovascular death) were analyzed separately by Cox proportional hazards modeling and competing risk regression (with death as a competing event), as described by Fine and Gray, 11 respectively. Prognostic importance of ECG LV strain and LVH is presented as cause-specific hazard ratios (HRs) with 95% confidence intervals (CIs). To evaluate the impact of ECG LV strain and LVH on long-term prognosis versus risk of adverse outcome when annually reexamined, predictive values were analyzed in 2 separate models: first with baseline values and then in a second model with serial values (based on annual follow-up). Both models were adjusted similarly for age, sex, peak aortic jet velocity and LV ejection fraction, echocardiographic LV mass, cholesterol levels, blood pressure, body mass index, and estimated glomerular filtration rate, estimated as glomerular filtration rate (mL/min per 1.73 2 )ϭ186ϫ[serum creatinine (mol/L)ϫ0.011312] Ϫ1.154 ϫ(age) Ϫ0.203 ϫ (0.742 if female). 12 Because of the central importance of AS, supplementary analyses were performed with adjustment for aortic valve area indexed by body surface area and mean aortic gradient. Because of the randomization therapy, we also adjusted for active versus placebo arm, but doing so did not significantly alter the impact of ECG variables (data not presented). In the model with ECG LV strain, we performed an additional adjustment for concomitant digoxin therapy (nϭ41) to account for its potential influence on appearance of ST/T segment (Cohn effect). Finally, we assessed whether ECG LVH by Ͼ1 criterion was associated with a worse outcome than that of LVH by only Sokolow-Lyon voltage or Cornell voltage-duration criteria. Proportionality and linearity assumption for each of the variables contained in the multivariable models were checked by testing the dependency of their relative risk estimate over time. Differences in risk of heart failure and myocardial infarction in patients with and without ECG LV strain and LVH, respectively, are shown by plots of cumulative incidence of heart failure and myocardial infarction with death as a competing event (with the use of the Fine and Gray method). A test of interaction between ECG LVH status and QRS duration category (as defined above) was conducted for each study outcome. Because of multiple testing, a 2-tailed PϽ0.01 was the preset significance level for interactions. For all other models, a 2-tailed PϽ0.05 was required for statistical significance.
Results
Baseline Characteristics
Baseline ECGs were available in 1563 patients. ECG criteria for LVH or T-wave inversion could be assessed in 1533 patients (Sokolow-Lyon voltage criteria in 1518, Cornell voltage-duration criteria in 1509, and T-wave inversion in 1442). Missing values were due to 100% ventricular pacing (nϭ10), censoring of ECG LV strain in presence of left bundle branch block (nϭ43), or poor quality of ECG (nϭ68). Mean age, sex, peak aortic jet velocity, and LV mass index did not differ between those with and without data for this study (data not presented). The 1533 patients with available data included 936 men (61.1%) and 597 women (38.9%) followed a mean of 4.3Ϯ0.8 years (6592 patient-years of follow-up); mean age was 67.4Ϯ9.6 years, and mean peak aortic jet velocity was 3.1Ϯ0.5 m/s. At inclusion, ECG LV strain was present in 340 patients (23.6%), with LVH in 260 (17.1%) by Sokolow-Lyon voltage criteria versus 220 (14.6%) by Cornell voltage-duration product criteria. Baseline characteristics in patients with and without ECG LV strain and LVH are presented in Table 1 .
Clinical Impact of ECG LV Strain and LVH
A total of 146 deaths occurred (9.5%), and 72 were categorized as cardiovascular (4.7%) with 27 of these as sudden cardiac deaths (1.8%, equal to an annual rate of 0.4%); 436 patients underwent AVR (28.5%), 45 suffered nonhemorrhagic stroke (2.9%), 39 suffered myocardial infarction (2.5%), and 35 were hospitalized for heart failure (2.3%). The proportions of subjects meeting end points in patients with LVH indicates left ventricular hypertrophy; SL, Sokolow-Lyon voltage criteria; CVDP, Cornell voltage-duration criteria; LV, left ventricular; BSA, body surface area; PWTD, posterior wall thickness in diastole; LVIDD, left ventricular internal dimension in diastole; IVSD, intraventricular septal thickness in diastole; triple product, left ventricular wall stress/mass/heart rate product; GFR, glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitor; and ARB, angiotensin receptor blocker.
*ECG strain defined as T-wave inversion in leads V 4 through V 6 . †Peak aortic jet velocity Ͻ3.0 m/s. and without baseline ECG LV strain or LVH by Sokolow-Lyon voltage or Cornell voltage-duration product criteria are presented in Table 2 . Associations with morbidity and mortality compared with no ECG LVH or LV strain, at baseline or by serial values, are given in Tables 3 through 5 . Risk of incident myocardial infarction in groups of patients with baseline ECG LV strain is presented in Figure 1 . The presence of ECG LV strain or LVH remained a strong predictor of poor prognosis also when adjusted by aortic valve area index and mean aortic gradient (Table 6 ). Of note, annual risks of hospitalization for heart failure in patients with baseline peak aortic jet velocities Ն3.0 m/s were Ϸ1.4% and Ϸ0.4% in those with and without additional ECG strain at inclusion, respectively (PϽ0.001). There was a trend toward increased risk of heart failure in patients without LVH but with prolonged QRS duration compared with normal QRS duration (end-of-study cumulative incidence of heart failure was 1.5% in patients without ECG LVH [nϭ1238] versus 3.9% in the similar group with prolonged QRS [nϭ51]). However, the predictive value of ECG LVH status did not depend on QRS duration (all PϭNS for interaction).
As such, no significant differences in rates of cardiovascular end points were observed by QRS category within the subgroups of patients with or without ECG LVH. At baseline and at annual in-study reexaminations, there were no detectable differences in serial values of ECG LV strain and LVH between patients randomized to simvastatin/ezetimibe combination versus placebo (all PϭNS). †Adjusted for age, gender, echocardiographic peak aortic jet velocity, left ventricular ejection fraction and left ventricular mass, cholesterol levels, systolic and diastolic blood pressure, estimated glomerular filtration rate, study drug, and body mass index, with baseline and serial values, respectively (based on annual reexamination).
Association of Baseline LVH With Clinical Outcomes
‡Reference without left ventricular hypertrophy by Sokolow-Lyon voltage criteria at baseline and by serial values, respectively (based on annual reexamination).
all-cause mortality (95% CI, 1.0 -3.5; PϽ0.05). Differences in risk of heart failure in groups of ECG LVH are given in Figure 2 . When adjusted by age, sex, peak aortic jet velocity, LV ejection fraction, blood pressure, echocardiographic LV mass, body mass index, cholesterol levels, study drug, and estimated glomerular filtration rate, patients with ECG LVH by both criteria, compared with those without signs of ECG LVH, had 5.8-fold higher risk of heart failure (95% CI, 2.0 -16.8), 2.0-fold higher risk of AVR (95% CI, 1.3-3.1; both Pϭ0.001), and 2.5-fold higher risk of the combined end point of myocardial infarction, heart failure, or cardiovascular death (95% CI, 1.3-4.9; Pϭ0.008).
Discussion
To the best of our knowledge, this study is the first to describe the predictive value of ECG LV strain and LVH during long-term follow-up of a large contemporary population of asymptomatic patients with mild to moderate AS. Several findings add to current knowledge. First, ECG LV strain adds prognostic information on myocardial infarction and heart failure before AVR. Second, ECG LVH adds to clinical and echocardiographic covariates for prediction of heart failure before AVR. Third, serial values of LVH by Sokolow-Lyon voltage and Cornell voltage-duration criteria were independently predictive of cardiovascular death as well as sudden cardiac death, respectively. In theory, ECG LV strain, as indicated by the relation to myocardial oxygen consumption and subsequent myocardial infarction, could reflect true subendocardial ischemia. The mechanisms may involve the following: (1) although coronary artery size increases with LV mass, 13 compensatory dilatation of coronary artery lumen may be insufficient to match the regional increase in LV mass 14 ; (2) there are lesser increases in arterioles and capillaries than in myocardial volume 15 ; and (3) increases in LV wall stress further increase myocardial O 2 demand. 16 Second, ECG LV strain could be a sign of otherwise silent coronary artery disease, likely to be present in some patients with AS. 17 Too few pre-AVR coronary angiograms were available to further evaluate the association of ECG LV strain with obstructive coronary †Adjusted for age, gender, echocardiographic peak aortic jet velocity, left ventricular ejection fraction and left ventricular mass, cholesterol levels, systolic and diastolic blood pressure, estimated glomerular filtration rate, study drug, and body mass index, with baseline and serial values, respectively (based on annual reexamination).
‡Reference without left ventricular hypertrophy by Cornell voltage-duration criteria at baseline and by serial values, respectively (based on annual reexamination). 6 . †Univariate analysis, with baseline and serial values, respectively (based on annual reexamination). ‡Adjusted for age, gender, echocardiographic peak aortic jet velocity, left ventricular ejection fraction and left ventricular mass, cholesterol levels, systolic and diastolic blood pressure, estimated glomerular filtration rate, study drug, digoxin, and body mass index, with baseline and serial values, respectively (based on annual reexamination).
§Reference without ECG strain at baseline and by serial values, respectively (based on annual reexamination).
artery disease per se. We speculate that ECG repolarization abnormalities reflect (1) the adverse impact of AS on LV structure and function; (2) the fact that increased myocyte volume can lead to abnormal repolarization; and (3) inadequate functional coronary flow due to regional changes in LV mass as well as reduced coronary flow reserve. The latter could be of importance in AS patients with angina, stationary echocardiographic changes, and a nonexplanatory coronary angiogram because 30% to 40% of angina in AS occurs in those with normal coronary arteries. 17 The close association of ECG strain with echocardiographic degree of AS severity as well as the differential impact of baseline ECG strain versus by annual reexamination argues that as AS advances, ECG strain might be indicative of LV pressure overload.
The observed different event rates in patients with and without ECG LVH suggest that LVH is fundamental for the risk stratification of asymptomatic AS. Experimental data have suggested a possible beneficial effect of simvastatin on cardiac hypertrophy in AS. 18 In the present study, there was no detectable difference in progression of ECG LV strain and LVH between patients randomized to simvastatin/ezetimibe combination versus placebo.
This study confirms the previously observed relation of ECG LVH to risk of developing symptoms of heart failure and ensuing AVR. 2 However, to the best of our knowledge, this study is the first to show that this is independent of echocardiographic and clinical covariates.
Our study has limitations. The SEAS study selected patients with asymptomatic AS who were relatively healthy because of the exclusion of several comorbidities. In particular, exclusion of known ischemic heart disease may have influenced the association of ECG LV strain and risk of myocardial infarction.
In conclusion, ECG criteria for LV strain and LVH are low-cost and widely available parameters for assessing risk of cardiovascular morbidity and mortality during watchful waiting in asymptomatic patients with AS. 
